Relations with public authorities and industry associations

Relations with Public Authorities

Durieu, UCB (photo)

Durieu, UCB

UCB made no significant corporate political contributions in any of the countries in which it operates. However, UCB Inc. has a federal political action committee which made contributions to political candidates in the U.S. Although UCB is not reporting significant issues or formal policy positions in 2016, UCB is actively connected with public policy makers, regulators and other stakeholders. In addition, no complaints on data privacy or breach thereof were received.

In 2016, three complaints were received for a deviation to industry voluntary codes regarding good promotional practices in the U.K., Sweden and Denmark. UCB identified appropriate preventative actions.

Countries in which UCB does business have laws and regulations regarding corporations’ involvement in the political process. Some of these laws set strict limits on contributions by corporations to political parties and candidates, whereas some laws prohibit them altogether.

In 2016, UCB was not involved in any action regarding laws and regulations relative to anti-competitive behavior, anti-trust or monopoly.

Relations with Industry Associations

Axel, living with epilepsy, DR Congo (photo)

Axel, living with epilepsy, DR Congo

UCB is a member of several global and local trade associations, e.g., Biotechnology Industry Organization (BIO, U.S.), European Federation of Pharmaceutical Industries and Associations (EFPIA, Belgium), Japan Pharmaceutical Manufacturers Association (JPMA, Japan), R&D-based Pharmaceutical Association Committee (RDPAC, China), and International Federation of Pharmaceutical Manufacturers & Associations (IFPMA, Switzerland), among others.

Considering the strategic importance, various taskforces, projects and committees dealing with current sector issues, e.g., Health Safety and Environment, Intellectual Property, Public Policy, Global Health and Compliance, among others, have been formed that include UCB employees. As an example, Jean-Christophe Tellier, UCB’s CEO, is a member of the board of EFPIA, and Chairman of the ‘Innovation’ EFPIA Board Sponsored Committee. He is also member of the Board of BIO, Washington (U.S.) and the Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Wavre (Belgium) to address solutions in the area of innovation, biotechnology and pharmaceuticals.

No funding beyond the routine annual memberships is provided.

UCB is also member of various chambers of commerce, associations and initiatives for sustainable development.

UCB is part of the Pharmaceutical Industry Initiative to Combat Crime (PIICC), an Interpol and pharmaceutical sector partnership with the focus on the prevention of all types of pharmaceutical crime including counterfeiting of both branded and generic drugs. UCB is also part of the Transported Asset Protection Association (TAPA), Rx-360 (an international pharmaceutical Supply Chain Consortium) and EFPIA Security Forum, which works together with other stakeholders, to allow for benchmarking, jointly identify and discuss solutions, and ensure product integrity and transparency across the supply chain.

In order to foster and to accelerate clinical study value-creation for persons living with severe chronic diseases, UCB partners with the TransCelerate Biopharma Inc. platform. This platform facilitates the interfaces on study-related matters with industry organizations, e.g., Association of Clinical Research Organization (ACRO), Coalition for Accelerating Standards and Therapies (CFAST), Clinical Trials Transformation Initiative (CTTI) and SCRS Society for Clinical Research Sites (SCRS), and global regulatory authorities. Representatives from clinical research organizations, patient programs, academia, pharmaceutical companies, and authorities outline adaptive research models offering patient-driven solutions with streamlined study design of innovative drugs.